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Background and Objective: Sphingosine 1-phosphate (S1P), and S1P receptor
modulator fingolimod have been suggested to play important cardioprotective role
in animal models of myocardial ischemia/reperfusion injuries. To understand the
cardioprotective function of S1P and its mechanism in vivo, we analyzed apoptotic,
inflammatory biomarkers, and myocardial fibrosis in an in vivo heterotopic rat heart
transplantation model.
Methods: Heterotopic heart transplantation is performed in 60 Sprague–Dawley (SD)
rats (350–400 g). The heart transplant recipients (n = 60) are categorized into
Group A (control) and Group B (fingolimod treated 1 mg/kg intravenous). At baseline
with 24 h after heart transplantation, blood and myocardial tissue are collected for
analysis of myocardial biomarkers, apoptosis, inflammatory markers, oxidative stress,
and phosphorylation of Akt/Erk/STAT-3 signaling pathways. Myocardial fibrosis was
investigated using Masson’s trichrome staining and L-hydroxyline.
Results: Fingolimod treatment activates both Reperfusion Injury Salvage Kinase (RISK)
and Survivor Activating Factor Enhancement (SAFE) pathways as evident from activation
of anti-apoptotic and anti-inflammatory pathways. Fingolimod treatment caused a
reduction in myocardial oxidative stress and hence cardiomyocyte apoptosis resulting in
a decrease in myocardial reperfusion injury. Moreover, a significant (p < 0.001) reduction
in collagen staining and hydroxyproline content was observed in fingolimod treated
animals 30 days after transplantation demonstrating a reduction in cardiac fibrosis.
Conclusion: S1P receptor activation with fingolimod activates anti-apoptotic and anti-
inflammatory pathways, leading to improved myocardial salvage causing a reduction in
cardiac fibrosis.
Keywords: sphingosine 1-phosphate, cardiac fibrosis, ischemia/reperfusion injury, cardioprotective, heart
transplantation
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INTRODUCTION
Heart transplantation is the ultimate treatment option for heart
failure (HF) (Koerner et al., 2000), which is a major health
problem worldwide, with a prevalence of 23 million worldwide
and 5.8 million in the United States alone (Benjamin et al., 2017).
HF has been singled out as an emerging epidemic in the world
with higher morbidity and mortality in 65 years old people and
elders (Roger, 2013). Cardiac fibrosis is one of the main factors in
the development and progression of HF. Therefore, targeting the
development and progression of cardiac fibrosis is a critical goal
in the treatment of HF (Miner and Miller, 2006; Opie et al., 2006).
Myocardial fibrosis can be categorized in two distinct
forms: (1) ischemia/reperfusion (I/R) injury as a result of
myocardial infarction, cardiac arrest, cardioplegic arrest,
and cardiac transplantation due to reparative process by
replacement of cardiomyocytes with collagen matrix and (2)
interstitial or perivascular fibrosis as a consequences of trauma
caused by volume or pressure overload, hypertrophic, or
dilated cardiomyopathies (Dobaczewski and Frangogiannis,
2009; Krenning et al., 2010). Most common cause of cardiac
dysfunction and mortality in cardiac transplant patients is
due to I/R injury (Murata et al., 2004; Tanaka et al., 2005).
Currently, low potassium solutions give some positive evidence
for better cardiac graft preservation and demonstrate attenuation
of grafted heart damage related to cold storage and I/R injury
(Rudd and Dobson, 2009). However, it has been observed that
this solution is not sufficient to protect from myocardial damage,
due to decreased cellular energy reserves, release of oxidants,
myocardial stunning, and myocardial dysfunction. Till now,
there is no efficient strategy that can reduce cardiac fibrosis due
to heart procurement and transplantation.
Sphingosine 1-phosphate (S1P) is a bioactive lipid that is
characterized by a peculiar mechanism of action. In fact S1P,
which is produced intracellularly, can act as an intracellular
mediator, whereas after its export outside the cell, it can act
as ligand of specific G-protein coupled receptors, which were
initially named endothelial differentiation gene (EDG) and
eventually renamed sphingosine 1-phosphate receptors (S1PRs).
Currently five S1P (S1P1-5) receptors are known. The S1P1,
S1P2, and S1P3 receptors are ubiquitously expressed whereas
the expression of S1P4 and S1P5 receptors is highly restricted
to the immune and nervous system (Ishii et al., 2004; Chun
et al., 2010). In cardiac tissue, S1P1 receptor is the predominant
receptor, whereas the expression of S1P2 and S1P3 receptors
is relatively very low (Zhang et al., 2007). Keul et al. (2016)
demonstrated in experimental study that S1P1 receptor is vital
for regulating cardiac function by modulating ion channels and
mediates myocardial protection by ischemic preconditioning.
Sphingosine 1-phosphate receptor modulator fingolimod is
a lipophilic agent derived from the fungus Isaria sinclairii
(Chiba and Adachi, 2012). S1P may also take part in
cardioprotection against I/R injury (Somers et al., 2012). S1PR
modulator fingolimod has potent anti-inflammatory and anti-
oxidant properties, by inhibiting oxygen free radical and leading
to reduced myocardial fibrosis, as a consequence of less
cardiomyocytes death (Aytan et al., 2016).
Fingolimod activates Reperfusion Injury Salvage Kinase
(RISK) and Survivor Activating Factor Enhancement (SAFE)
pathways, leading to inhibition of pro-apoptotic proteins and
activation of anti-apoptotic proteins (Liu et al., 2013). We
hypothesized that pre-conditioning with fingolimod might
achieve optimal cardioprotection and reduce fibrosis by
activating anti-apoptotic, anti-inflammatory, and pro-survival
pathways. Our aim was to investigate the cardioprotective role of
fingolimod on apoptosis, inflammation, oxidative stress, nitrative
stress, activation of Akt and Erk1/2 signaling pathways, and
cardiac fibrosis in rat heterotopic heart transplantation model.
MATERIALS AND METHODS
Animals
Sprague–Dawley (SD) Rats (350–400 g) were obtained from
Harlan Laboratories (Udine, Italy). The rats were fed standard
rat chow with an access to ad libitum. The rats were housed at a
density of 4–6 per cage and maintained on a 12 h light/dark cycle
at 21◦C. All the animal experiments were carried out according to
the regulations (Declaration of Helsinki and “Guide for the Care
and Use of Laboratory Animals” – Institute of Laboratory Animal
Resources – National Institutes of Health) after experimental
protocols were reviewed and approved by the Ethics Committee
of University of Verona and the Italian Ministry of Health
(341/2016-PR).
Experimental Design
In this study, 120 animals were used, 60 donors and 60
recipients. The 60 recipient rats were divided into two main
groups (control group and fingolimod treated group). The
experimental protocol used was as follows: the animals were
pre-treated 15 min before heart explantation, by intravenous
(i.v.) injection of either saline (control group) or fingolimod
[treated group, 1 mg/kg; (Santos-Gallego et al., 2016)]. Hearts
were harvested and transplantation was performed within 1 h.
Abdominal cavity was closed and animals were allowed to
recover. Transplanted animals were then divided into two
subgroups: first subgroup was sacrificed after 24 h of R and
second group was sacrificed 30 days after transplant (n = 15
for each group). The 24 h group was used to collect blood
aliquots and hearts for cardiac, inflammatory, apoptotic, and
oxidative markers while 30 day group was used to study cardiac
fibrosis using Masson’s trichrome staining and L-hydroxyproline.
Schematic presentation of the experimental plan is illustrated in
Figure 1.
Surgical Technique
Recipient rats were anesthetized with 5% isoflurane in 50%
O2 administered through a facial mask. Median abdominal
incision was practiced. Sub-renal aortic and inferior vena cava
(IVC) are exposed and isolated. Two vascular clamps were
positioned superiorly and inferiorly to the site of transplanted
heart implantation. Two adequate incisions were performed on
aorta and IVC and the lumen of the two vessels was perfused with
saline solution and heparin to avoid thrombus formation.
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FIGURE 1 | Schematic presentation of experimental design.
While an operator sets up the recipient rat another
operator prepares the donor rat. Anesthesia was performed by
intraperitoneal administration of sodium thiopental (Pentotal R©)
60 mg/kg. The animal was intubated orotracheally with an
atraumatic tube consisting of a 16 G venous cannula and
was mechanically ventilated (Harvard Model 687; Harvard
Apparatus, Holliston, MA, United States). Tidal volume was set
to 10 ml/kg and respiratory rate 60 breaths/min with an air–
oxygen mixture/FiO2 = 0.5). Anesthesia was maintained with
isoflurane (2%) during the whole procedure.
The chest was opened through median sternotomy and heart
was exposed. The right superior vena cava (SVC) was tied with
Ticron 3.0 suture, ascending aorta and pulmonary artery are
resected at 3–4 mm from their origin with an angled scissor.
Ten milliliters of cold S. Thomas cardioplegic solution was
injected to stop the heartbeat, and after that IVC was tied and
closed with Ticron 3.0 suture. The heart was then lifted up and
with a single ligature pulmonary veins and left SVC were tied and
closed. The heart was immediately dipped in a cold cardioplegia
bath and another 10 ml of S. Thomas solution was injected into
the heart through ascending aorta.
The explanted heart was then placed in the abdomen of the
recipient rat and positioned in order to avoid twisting. The
first anastomosis was performed between the abdominal aorta
of the recipient rat and the ascending aorta of the donor heart
using polypropylene 8.0 continuous suture. After completing this
anastomosis, the anastomosis between IVC of the recipient rat
and the pulmonary artery of the donor heart was performed. The
heart was topically cooled by irrigating intermittently with saline
solution at 4◦C during the transplantation period. Time for the
execution of the two anastomoses was between 35 and 40 min.
Afterward, the vascular clamps were removed and if no stenosis
or bleeding is evident, the implanted heart spontaneously starts
beating. Warm saline solution was poured into the abdominal
cavity and the abdomen was closed through continuous suture of
the muscle wall and of the skin with a Polypropylene 4.0 suture.
Sedation was suspended and after few minutes rat wakes up.
TUNEL Assay
Paraffin-embedded hearts from control and treated animals
were deparaffinised with xylene and gradually hydrated in
ethanol (EtOH) solutions (100, 95, 70, and 50%). Apoptotic
cells were stained with terminal deoxynucleotidyl transferase
dUTP nick end labeling (TUNEL) assay using the In Situ Cell
Death Detection Kit (Roche, Cat. 11684809910). Nuclei were
stained with Hoechst 33342 solution and quantified using ImageJ
software (United States National Institutes of Health).
Histology and Myocardial Fibrosis
Quantification
Myocardial tissues from the left ventricle were fixed in 10%
formaldehyde in phosphate-buffered saline (PBS) (pH 7.2), after
fixation these blocks were embedded in paraffin and 3 µm thick
sections were prepared for histological staining (Song et al.,
2014). Myocyte diameter was determined from haematoxylin–
eosin stained ventricle sections and expressed in micrometer.
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Cardiac fibrosis was analyzed from tissue sections stained with
Masson’s trichrome staining.
L-Hydroxyproline Assay
The L-hydroxyproline content is a type of protein that indicates
collagen deposition. Using the L-hydroxyproline assay, collagen
deposition was evaluated to assess tissue damage. Cardiac tissue
was minced and hydrolyzed with HCl at 125◦C and 200 psi
for 2 h. After serial evaporation and addition of water final
product was reconstituted in 5 ml distilled water. Each sample
(2-ml aliquot) was oxidized with 1 ml of chloramine-T for
20 min. The remaining chloramine-T was neutralized with 1 ml
of perchloric acid (3.0 M). The sample was mixed with 1 ml of
p-dimethylaminobenzaldehyde and incubated in a hot water bath
at 60◦C and cooled to room temperature (RT) afterward. The
absorbance was measured at 557 nm and the L-hydroxyproline
concentration was measured using a standard curve.
Western Blotting
The heart tissue was homogenized in buffer containing 1%
Triton X-100 with phosphatase and protease inhibitors cocktail
(Sigma–Aldrich, Milan, Italy) as described previously (Giani
et al., 2007). The tissue extracts were centrifuged at 16,000× g for
15 min at 4◦C to remove the insoluble material, and supernatants
were collected in separate aliquots. Protein concentration was
measured by using the BCA Assay Kit (Beyotime Institute of
Biotechnology, China) according to manufacturer’s instruction.
The phosphorylation levels of Akt1/2 and ERK1/2 equal amounts
of solubilized proteins (35 µg) were denatured by boiling for
5 min at 100◦C in reducing buffer, resolved by SDS-PAGE,
and protein transferred to polyvinylidene difluoride (PVDF)
membranes. After transfer, membranes were blocked in blocking
solution (5% BSA in TBS-T) for 1 h. The membranes were
then incubated with primary antibodies (1:1000) overnight at
4◦C. The membranes were washed with TBS-T and incubated
with HRP-conjugated secondary antibodies (1:10,000). The
bands were visualized by using Syngene Western Blotting
detection system (Syngene, Cambridge, United Kingdom). The
quantification of protein band densities was performed by
ImageJ software (United States National Institutes of Health).
GAPDH was used as loading control. The antibodies used
were: total Akt1/2 (Abcam, Cambridge, United Kingdom), anti-
phosphorylated Akt1/2 (rabbit, Cell Signaling), total ERK1/2
(Abcam, Cambridge, United Kingdom), anti-phosphorylated
ERK1/2 (Cell Signaling, Denver, CO, United States), anti-STAT3
(Cell signaling, Denver, CO, United States), and HRP-conjugated
goat anti-rabbit IgG (Abcam, Cambridge, United Kingdom).
The remaining reagents were purchased from Sigma–Aldrich
(St. Louis, MO, United States).
Immunohistochemical Staining
Paraffin-embedded left ventricle sections were heated at 60◦C
for 1 h and rehydrated with xylene for 20 min and with
graded EtOH solutions (100, 95, 70, and 50%). Antigen retrieval
solution was applied (0.01 M citrate buffer, pH 6.0) for
30 min in a boiling water bath, followed by slow cooling
and rinsing with PBS. Endogenous peroxidase activity was
suppressed by incubation with 3% hydrogen peroxide in TBS-
T. Myocardial tissue sections were incubated with primary
antibodies Bax (Abcam, Cambridge, United Kingdom) and Bcl-
2 (Dako, Glostrup, Denmark) were incubated overnight at 4◦C.
Afterward, the sections were incubated with HRP-conjugated
secondary antibody for 30 min, and diaminobenzidine and
hydrogen peroxide chromogen substrate (DAB, Dako Corp.). All
sections were counterstained with haematoxylin and mounted.
The negative controls were incubated with non-immune rabbit
IgG instead of primary antibody. All histological sections were
studied using a light microscope Nikon E400 (Nikon Instrument
Group, Melville, NY, United States).
Detection of Cardiac Enzymes and
Oxidative Stress
After transplantation and R, blood was taken from the carotid
artery and was placed at RT for 30 min to allow coagulation.
The serum was then collected by centrifugation and placed at
−70◦C for preservation. Serum CK-MB and cardiac troponin-
I were measured using CK-MB and Cardiac Troponin-I Assay
Kits (Sigma–Aldrich, United Kingdom) and Oxidative Stress
Kit (Thermo Fisher Scientific, United States) according to
manufacturer’s instruction.
Statistical Analysis
To compare treatment and control groups, all measurements
and results are presented as mean ± SEM. Both groups
were compared using Student’s t-test or Mann–Whitney U
nonparametric test. A p-value of less than 0.05 was considered to
be statistically significant. Analyses were performed using SPSS
software version 21 (SPSS Inc., Chicago, IL, United States).
RESULTS
Expression of Bcl-2 and Bax
Myocyte apoptosis is hallmark of reperfusion injury after
HT. Therefore, the expression of pro-apoptotic Bax and anti-
apoptotic Bcl-2 was analyzed in our HT model. As presented in
Figure 2, after 24 h of reperfusion there was a massive expression
of Bax in control group (Figure 2B) which was abolished by S1PR
agonist fingolimod (Figures 2C,G). Likewise, the expression of
anti-apoptotic Bcl-2 was significantly enhanced in fingolimod
treated group (Figures 2E,F,H).
Effect of Fingolimod on Apoptosis
Myocyte apoptosis was analyzed by TUNEL assay. As shown
in Figures 3D,E,F massive apoptosis was observed in the
control group after 24 h of transplantation compared to healthy
non-operated hearts (Figures 3A–C). This was significantly
attenuated in fingolimod group (Figures 3G,H,I).
Collagen Deposition and Cardiac
Fibrosis
Development of cardiac fibrosis was analyzed by measuring
the collagen deposition in the cardiac tissue after 30 days
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FIGURE 2 | Representative images (n = 15 for each group control and treated group) of myocardial tissue expression levels of Bcl-2 and Bax after 60 min of
ischemia and 24 h reperfusion in fingolimod treated and control group. The protein expression levels of Bcl-2 and Bax were determined by an immunohistochemistry.
(A,D) Negative control, (B,E) Bax and Bcl-2 expression in HT-control group, respectively, (C,F) Bax and Bcl-2 expression in HT-fingolimod treated group, (G,H)
graphical presentation of Bax and Bcl-2 protein in fingolimod treated and control group. Data presented as a mean ± SEM. P-value < 0.05 considered as
significant. (∗p < 0.05 and ∗∗p < 0.001, treated vs. control).
FIGURE 3 | Representative images (n = 15 for each group control and treated group) of immunofluorescent staining for TUNEL-positive nuclei in negative control,
HT-control, HT-fingolimod treated groups. (A,D,G) Shows only DAPI in myocardial tissue, (B,E,H) TUNEL signals, and (C,F,I) merged images. TUNEL-positive
myocytes were much lower in numbers frequently in control HT group than in HT-fingolimod treated group. Green and yellow arrows indicate apoptotic nuclei and
apoptotic nuclei merged with DAPI, respectively. Original magnification 40×. Data presented as a mean ± SEM. P-value < 0.05 considered as significant.
(∗∗p < 0.001, treated vs. control).
of the reperfusion. Collagen deposition was analyzed by
Masson’s trichrome staining. Extensive collagen deposition in
the ventricular tissue as indicated by blue staining was observed
after 30 days of HT (Figures 4A,B). Interestingly, hearts
previously perfused with fingolimod before transplantation were
protected from fibrosis as indicated by much reduced collagen
deposition (Figures 4B,C). L-Hydroxyproline assay has been
performed to investigate collagen content in myocardial tissue
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FIGURE 4 | Representative photomicrograph (n = 15 for each group control and treated group) showing the collagen deposition in rats related to HT I/R injury (20×
magnification). Fingolimod decreased post-HT myocardial in myocardial fibrosis. The viable myocardium is stained bright red. Fibrosis is stained bright blue. (A); HT
control after 30 days of reperfusion and (B); HT fingolimod treated after 30 days of reperfusion. (C) Graphical presentation of cardiac fibrosis, and (D) graphical
presentation of L-hydroxyproline at early and late phase of R injury related to transplantation. Data presented as a mean ± SEM. P-value < 0.05 considered as
significant (∗p < 0.05 and ∗∗p < 0.001, treated vs. control).
post-cardiac transplantation at early and late phase of reperfusion
(Figure 4D). This quantitative assay confirmed our histological
findings that showed reduction of cardiac fibrosis with treatment
of fingolimod prior to heart transplantation.
Serum Levels of Inflammatory Mediators
The inflammatory mediator’s contribution in tissue injury has
previously been identified in the heterotopic HT models (Mori
et al., 2014). During heterotopic HT-related I/R injury a
significant elevation in the plasma levels of cytokines mainly
TNF-α, IL-1β, IL-6, and ICAM-1 may result (Vinten-Johansen
et al., 2007). Like previous reports, increased serum levels of these
mediators were observed in HT animals after 24 h of R (Figure 5)
which were significantly attenuated in animals transplanted with
hearts pre-treated with fingolimod.
Effect of Fingolimod on Erk42/44, Akt1/2,
and STAT3 Phosphorylation
Since fingolimod pre-treatment caused a profound reduction
in apoptosis of myocardial tissue, activation of pro-survival
pathways was analyzed by measuring the phosphorylation state
of the pro-survival Erk, Akt, and STAT3. As shown in Figure 6,
pre-treatment with fingolimod resulted in a significant increase
in phosphorylation of Erk42/44, Akt1/2, and STAT3.
Oxidative Stress
Uncontrolled production of reactive oxygen species (ROS) is one
of the major causes inducing apoptosis in cardiac tissue after
R. In order to evaluate whether fingolimod-mediated cardiac
protection is due to its effect on cardiac ROS generation, levels of
ROS and aldehydes (lipid peroxidation derivatives) were analyzed
in the frozen perfused myocardial sample. As shown in Figure 7,
levels of ROS and malondialdehyde were significantly reduced in
cardiac tissues pre-treated with fingolimod.
DISCUSSION
In this study, we investigated cardioprotective and anti-fibrotic
effect of pharmacological preconditioning during prolonged
organ preservation using an in vivo heart transplantation model.
We found that fingolimod, a S1PR modulator, efficiently works
as ischemic preconditioning agent. Our findings suggested that
fingolimod plays an important role in the reduction of apoptosis,
inflammation, oxidative stress, and cardiac fibrosis. To the
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FIGURE 5 | Myocardial production of TNF-α (A), IL-6 (B), ICAM-1 (C), and IL-1β (D) after 24 h of R. (A) HT model without fingolimod treatment shows high
expression of TNF-α as compared to fingolimod treatment. (B) HT-R induced significant high IL-6 after 24 h of R compared with the fingolimod treated. (C)
Fingolimod treated group remarkably reduced the production of the ICAM-1 release as compared to Control. (D) This section of the panel presents production of
1L-1β higher in control vs. fingolimod treated group in HT-R group. Each bar height represents the mean ± SEM (each group n = 15) (##p ≤ 0.01 vs. baseline,
∗p ≤ 0.05 and ∗∗p ≤ 0.001 vs. HT-control group).
best of our knowledge, the present study is first to investigate
cardioprotective and anti-fibrotic role of fingolimod in preclinical
heart transplantation model.
Fingolimod is one of the FDA approved treatment option
in prevention of multiple sclerosis relapse (Bergvall et al., 2014;
Totaro et al., 2015). In addition to its immune-modulating
effect, fingolimod has a number of additional useful actions,
including anti-inflammatory, anti-apoptotic, anti-oxidative, and
anti-nitrative stress (Behjati et al., 2014). These properties are
predicted to improve the myocardial insult related to I/R during
heart transplantation. Previous studies have reported that pre-
treatment with S1PR modulator protected myocardium from
I/R injury (Li et al., 2016). In the present study, we show that
fingolimod treatment remarkably reduced myocardial fibrosis.
The role of fingolimod in cytoprotection in different organs
has been reported including pancreatic transplantation in
diabetics (Tchorsh-Yutsis et al., 2009), fingolimod pre-treatment
reduces I/R injury in liver transplantation (Anselmo et al., 2002),
in renal transplantation (Tedesco-Silva et al., 2006), and against
acute ischemic stroke (Zhu et al., 2015). These all models are
suggestive for cytoprotective role of fingolimod in I/R injury.
Reperfusion after transient I in myocardium leads to
cardiomyocytes apoptosis and cardiac dysfunction (Khan et al.,
2006; Oh et al., 2013). TUNEL assay is the gold standard method
(Darzynkiewicz et al., 2008) to measure the extent of apoptosis.
Consistent with previous results, the transplanted hearts treated
with fingolimod 15 min before explant expressed a lower
frequency of TUNEL positive nuclei compared to control. This
indicates the cardioprotective role of fingolimod by activating
anti-apoptotic cascade.
In order to investigate the possible mechanisms of cardio-
protective effects of fingolimod, its effects on activation of
survival pathways were analyzed. Activation of the RISK
and SAFE pathways by fingolimod has previously been
reported (Lecour et al., 2002; Zhang et al., 2007). The RISK
(Akt1/2, Erk1/2, and GSK 3β) and SAFE pathways (JAK
and STAT3) are the main sources for regulation of apoptotic
pathways because of control on mitochondrial permeability
transition pore (Heusch et al., 2011; Heusch, 2013, 2015).
Consistent with previous findings, activation of RISK and
SAFE signaling pathways was observed, followed by decreased
level of apoptosis in the treated group as compared to
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FIGURE 6 | Representative Western blot images (A) and graphical presentation of the ratio of pAkt1/2/Akt, pErk42/44/Erk, and pSTAT-3/STAT-3 (B). Myocardial
samples were collected at the end of 24 h reperfusion. Activation of Akt1/2, Erk42/44, and STAT-3 pathways in fingolimod treated group was measured by change in
fold of phosphorylation with respect to control group. The GAPDH blot demonstrates that there was no change in the expression of total ERK1/2, total Akt1/2, and
total STAT-3 in the treated group with respect to control group. Values are means ± SEM (∗p ≤ 0.05, ∗∗p ≤ 0.001) (n = 15 each group).
FIGURE 7 | Oxidative stress comparison of oxidative stress in heterotopic transplantation model with and without fingolimod treatment (n = 15 each group). ROS,
reactive oxygen species; HT, heterotopic transplantation; FTY720, fingolimod; Carr. unit. Carratelli unit (∗∗p ≤ 0.001, ∗p ≤ 0.05).
control. The inhibition of pro-apoptotic protein Bax enhanced
immunostaining for anti-apoptotic protein Bcl-2 was found
after 24 h of reperfusion in heterotopic transplanted heart
tissue.
In this study, administration of fingolimod demonstrated
inhibition of apoptosis by inhibiting inflammation and oxidative
stress. In our investigations, on molecular and protein level
both cardioprotection have been observed. According to previous
reports, S1P and its agonist has important role in reduction
of inflammatory mediators in I/R injury (Stone et al., 2015).
Different models have been tested for immunosuppression
including the porcine model of I/R, and spontaneous obstructive
coronary atherosclerosis murine model showed the better
myocardial protection and decrease inflammatory markers
in the fingolimod-treated group. We measured inflammatory
response in blood and heart tissue. In blood, we found
the reduction of neutrophils and lymphocytes. Santos-Gallego
et al. (2016) found improved myocardial salvage in animals
using fingolimod and suggested an immunomodulatory role of
fingolimod by activation of S1PRs. The inflammatory mechanism
is one of the key factors in I/R injury. The ICAM-1, IL-6,
and TNF-α contribute in as a pro-inflammatory cytokines to
develop myocardial damage (Bonney et al., 2013; Li et al.,
2013; Markowski et al., 2013). The correlation between anti-
inflammatory effects of fingolimod with reduction in fibrosis is
evident in our experiment.
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It is well established that I/R causes myocardial injury
due to oxidative stress (Ferrari et al., 2004; Ansley and
Wang, 2013). Oxidative stress is also a major factor involved
in apoptosis. Treatment with fingolimod reduces apoptosis
in the I/R model (Chamorro et al., 2016; Santos-Gallego
et al., 2016). This reduction in apoptosis is mediated via
both RISK and SAFE pathways (Santos-Gallego et al.,
2016). In our transplantation experiments, decreased level
of malondialdehyde and ROS in the fingolimod-treated
group was observed suggesting the reduction in oxidative
stress is one of the cardioprotective mechanisms of S1PR
modulators.
Myocardial I/R also produces nitric oxide synthase that
releases nitric oxide which reacts with ROS as a result, forms
toxic peroxynitrite leading to necrosis and apoptosis (Nour
et al., 2013). Fingolimod treatment partially attenuates nitrative
stress in transplanted myocardium (Colombo et al., 2014).
Present findings suggest fingolimod can be efficiently used as a
preconditioning agent to improve myocardial salvage.
Together, all these results are suggestive of the myocardial
protective role having reduced fibrosis of fingolimod in global
I–R. Fingolimod is the only available FDA-approved agent,
containing S1PR agonist for prevention of multiple sclerosis
relapses. According to our recent study on characterization and
expression of S1PRs in human and rat (Ahmed et al., 2017)
indicates potential translation of current study into clinical
trials.
CONCLUSION
In conclusion, our study supports the cardioprotective role
of S1PR modulator fingolimod for reduction in apoptosis,
inflammation, oxidative stress, and fibrosis in an experimental
model of heterotopic HT. This study provides insight for
activation of cellular signaling pathways including RISK and
SAFE pathways following significantly reduced cardiac fibrosis in
long-term R.
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